Key result
GLP-1 receptor agonists and SGLT2 inhibitors demonstrated moderate absolute treatment benefits for a composite renal outcome compared to placebo, with meta-NNTs of 85 and 104 at 36 months.
Why the study?
Absolute treatment benefits, expressed as numbers needed to treat, of GLP-1 receptor agonists and SGLT2 inhibitors on renal outcomes remained uncertain.
Do GLP-1 receptor agonists and SGLT2 inhibitors reduce composite renal outcomes compared to placebo in high-risk patients with type 2 diabetes, heart failure, or chronic kidney disease?
Meta-Analysis (n=90,865)
Yes
Do GLP-1 receptor agonists and SGLT2 inhibitors reduce composite renal outcomes compared to placebo in high-risk patients with type 2 diabetes, heart failure, or chronic kidney disease?
GLP-1 receptor agonists and SGLT2 inhibitors provide moderate and similar absolute treatment benefits for preventing composite renal outcomes, with NNTs of 85 and 104 respectively at 36 months.
Answers are grounded in this paper and cite their sources.
Both yield moderate, comparable renal benefits (NNT ~85–104); extends relative-effect data with absolute estimates for shared decision-making.
Background Absolute treatment benefits—expressed as numbers needed to treat—of the glucose lowering and cardiovascular drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose transporter 2 (SGLT2) inhibitors on renal outcomes remain uncertain. With the present meta-analysis of digitalized individual patient data, we aimed to display and compare numbers needed to treat of both drugs on a composite renal outcome. Methods From Kaplan–Meier plots of major cardiovascular outcome trials of GLP-1 receptor agonists and SGLT2 inhibitors vs. placebo, we digitalized individual patient time-to-event information on composite renal outcomes with WebPlotDigitizer 4.2; numbers needed to treat from individual cardiovascular outcome trials were estimated using parametric Weibull regression models and compared to original data. Random-effects meta-analysis generated meta-numbers needed to treat with 95% confidence intervals (CI). Results Twelve cardiovascular outcome trials (three for GLP-1 receptor agonists, nine for SGLT2 inhibitors) comprising 90,865 participants were included. Eight trials were conducted in primary type 2 diabetes populations, two in a primary heart failure and two in a primary chronic kidney disease population. Mean estimated glomerular filtration rate at baseline ranged between 37.3 and 85.3 ml/min/1.73 m 2 . Meta-analyses estimated meta-numbers needed to treat of 85 (95% CI 60; 145) for GLP-1 receptor agonists and 104 (95% CI 81; 147) for SGLT2 inhibitors for the composite renal outcome at the overall median follow-up time of 36 months. Conclusion The present meta-analysis of digitalized individual patient data revealed moderate and similar absolute treatment benefits of GLP-1 receptor agonists and SGLT2 inhibitors compared to placebo for a composite renal outcome.
No takes yet. Share an insight, caveat, or question.
Brockmeyer et al. (2024) conducted a meta-analysis in Type 2 diabetes, heart failure, or chronic kidney disease (n=90,865). GLP-1 receptor agonists and SGLT2 inhibitors vs. Placebo was evaluated on Composite renal outcome (NNT 85, 95% CI 60-145). GLP-1 receptor agonists and SGLT2 inhibitors demonstrated moderate absolute treatment benefits for a composite renal outcome compared to placebo, with meta-NNTs of 85 and 104 at 36 months.
Synapse has enriched 10 related papers. Consider them for comparative context: